Refractory migraine and chronic migraine: Pathophysiological mechanisms

Headache

Volumn 48, Issue 6, 2008, Pages 799-804

  Goadsby, Peter J ^a   Hargreaves, Richard ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Brain; Migraine; Trigeminal

Indexed keywords

ANTIMIGRAINE AGENT; RIZATRIPTAN; SUMATRIPTAN;

DRUG EFFECT; GENE MUTATION; HEADACHE; HUMAN; MIGRAINE; NERVE STIMULATION; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SPREADING CORTICAL DEPRESSION; TRANSFORMED MIGRAINE;

CENTRAL NERVOUS SYSTEM; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS; PAIN, INTRACTABLE; POSITRON-EMISSION TOMOGRAPHY; TREATMENT FAILURE;

EID: 44849134833     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.01157.x     Document Type: Review

References (64)

1. Goadsby PJ, Oshinsky M. The pathophysiology of migraine. In : Silberstein SD, Lipton RB, Dodick D, eds. Wolff's Headache and Other Head Pain, 8th edn. New York : Oxford 2008 : 105 119.
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001 41 : 646 657.
3. Menken M, Munsat TL, Toole JF. The global burden of disease study - implications for neurology. Arch Neurol. 2000 57 : 418 420.
4. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003 290 : 2443 2454.
5. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (second edition). Cephalalgia. 2004 24 (Suppl. 1 1 160.
6. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 26 : 742 746.
7. Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006 26 : 1168 1170.
8. Lipton RB, SIlberstein SD, Saper J, Bigal ME, Goadsby PJ. Why headache treatment fails? Neurology. 2003 60 : 1064 1070.
9. Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice, 2nd edn. London : Martin Dunitz 2002.
10. Lance JW, Goadsby PJ. Mechanism and Management of Headache, 7th edn. New York : Elsevier 2005.
11. Russell MB. Genetic epidemiology of migraine and cluster headache. Cephalalgia. 1997 17 : 683 701.
12. Scher AI, Terwindt GM, Verschuren WM, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol. 2006 59 : 372 375.
13. 2+ channel gene CACNL1A4. Cell. 1996 87 : 543 552.
14. Marconi R, De Fusco M, Aridon P, et al. Familial hemiplegic migraine type 2 is linked to 0.9Mb region on chromosome 1q23. Ann Neurol. 2003 53 : 376 381.
15. + pump α2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003 33 : 192 196.
16. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A causes familial hemiplegic migraine. Lancet. 2005 366 : 371 377.
17. van den Maagdenberg AMJM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knock-in migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004 41 : 701 710.
18. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006 59 : 652 661.
19. Mathew R, Chami L, Bergerot A, van den Maagdenberg AMJM, Ferrari MD, Goadsby PJ. Reduced expression of calcitonin gene related peptide (CGRP) in mice with the familial hemiplegic migraine (FHM) 1 mutation. Cephalalgia. 2007 27 : 1190.
20. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987 27 : 416 420.
21. Veloso F, Kumar K, Toth C. Headache secondary to deep brain implantation. Headache. 1998 38 : 507 515.
22. Welch KM, Nagesh V, Aurora S, Gelman N. Periaqueductal grey matter dysfunction in migraine: Cause or the burden of illness? Headache. 2001 41 : 629 637.
23. Goadsby PJ. Neurovascular headache and a midbrain vascular malformation-evidence for a role of the brainstem in chronic migraine. Cephalalgia. 2002 22 : 107 111.
24. Afridi S, Goadsby PJ. New onset migraine with a brainstem cavernous angioma. J Neurol Neurosurg Psychiat. 2003 74 : 680 682.
25. Obermann M, Gizewski ER, Limmroth V, Diener H-C, Katsarava Z. Symptomatic migraine and pontine vascular malformation: Evidence for a key role of the brainstem in the pathophysiology of chronic migraine. Cephalalgia. 2006 26 : 763 766.
26. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nature Med. 1995 1 : 658 660.
27. Afridi S, Giffin NJ, Kaube H, et al. A PET study in spontaneous migraine. Arch Neurol. 2005 62 : 1270 1275.
28. Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Brainstem and hypothalamic activation in spontaneous migraine attacks. Cephalalgia. 2004 24 : 775 814.
29. Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Hypothalamic activation in spontaneous migraine attacks. Headache. 2007 47 : 1418 1426.
30. Matharu MS, Bartsch T, Ward N, Frackowiak RSJ, Weiner RL, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: A PET study. Brain. 2004 127 : 220 230.
31. Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet. 2001 357 : 1016 1017.
32. Afridi S, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005 128 : 932 939.
33. Matharu MS, Good CD, May A, Bahra A, Goadsby PJ. No change in the structure of the brain in migraine: A voxel-based morphometric study. Eur J Neurol. 2003 10 : 53 58.
34. Granziera C, DaSilva AFM, Snyder J, Tuch DS, Hadjikhani N. Anatomical alterations of the visual motion processing network in migraine with and without aura. PLoS Med. 2006 3 : e402.
35. Kurth T. Migraine and ischaemic vascular events. Cephalalgia. 2007 27 : 965 975.
36. Diener HC, Kurth T, Dodick D. Patent foramen ovale and migraine. Curr Pain Headache Rep. 2007 11 : 236 240.
37. Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004 291 : 427 434.
38. Rozen TD. Vanishing cerebellar infarcts in a migraine patient. Cephalalgia. 2007 27 : 557 560.
39. Silberstein SD, Olesen J, Bousser MG, et al. The International Classification of Headache Disorders 2nd Edition (ICHD-II) - revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005 25 : 460 465.
40. Scher AI, Lipton RB, Stewart W. Risk factors for chronic daily headache. Curr Pain Headache Rep. 2002 6 : 486 491.
41. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular analgesic use? Headache. 2003 43 : 179 190.
42. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001 41 : 303 309.
43. Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in cluster headache patients. Neurology. 2006 67 : 109 113.
44. Goadsby PJ. Is medication-overuse headache a distinct biological entity? Nat Clin Pract Neurol. 2006 2 : 401.
45. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia. 2006 26 : 1192 1198.
46. Diener H-C, Bussone G, van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007 27 : 814 823.
47. Silberstein SD, Lipton RB, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache. 2007 47 : 170 180.
48. Schoenen J, Wang W, Albert A, Delwaide PJ. Potentiation instead of habituation characterizes visual evoked potentials in migraine patients between attacks. Eur J Neurol. 1995 2 : 115 122.
49. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of the auditory cortical evoked potentials is pronounced in migraine: An indication of cortical potentiation and low serotonergic transmission? Neurology. 1996 46 : 1404 1409.
50. Wang W, Schoenen J. Interictal potentiation of passive "oddball" auditory event-related potentials in migraine. Cephalalgia. 1998 18 : 261 265.
51. Afra J, Sandor P, Schoenen J. Habituation of visual and intensity dependence of cortical auditory evoked potentials tend to normalise just before and during migraine attacks. Cephalalgia. 2000 20 : 347.
52. Sandor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: Differential effects on the intensity dependence of auditory evoked cortical potentials. Headache. 2000 40 : 30 35.
53. Di Clemente L, Coppola G, Magis D, et al. Interictal habituation deficit of the nociceptive blink reflex: An endophenotypic marker for presymptomatic migraine? Brain. 2007 130 : 765 770.
54. Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain. 2006 129 : 543 550.
55. Magis D, Ambrosini A, Bendtsen L, Ertas M, Kaube H, Schoenen J. Evaluation and proposal for optimalization of neurophysiological tests in migraine: Part 1 - electrophysiological tests. Cephalalgia. 2007 27 : 1323 1338.
56. Magis D, Bendtsen L, Goadsby PJ, et al. Evaluation and proposal for opimization of neurophysiological tests in migraine: Part 2 - neuroimaging and the nitroglycerin test. Cephalalgia. 2007 27 : 1339 1359.
57. Ferrari MD. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. New Engl J Med. 1991 325 : 316 321.
58. Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000 62 : 509 525.
59. 1B receptor polymorphism and clinical response to sumatriptan. Headache. 1998 38 : 288 291.
60. Velati D, Viana M, Cresta S, et al. 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. Eur J Pharmacol. 2007 580 : 43 47.
61. 1F receptor gene: No evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet. 1998 77 : 415 420.
62. Asuni C, Cherchi A, Congiu D, Piccardi MP, Del Zompo M, Stochino ME. Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain. 2007 8 : 185 189.
63. Bergerot A, Holland PR, Akerman S, et al. Animal models of migraine. Looking at the component parts of a complex disorder. Eur J Neurosci. 2006 24 : 1517 1534.
64. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003 23 : 820 824.